title: [Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].
abstract: Chronic graft versus host disease (GVHD) is still the main cause of long-term non-neoplastic morbidity and mortality in patients receiving an allogeneic hematopoietic stem cell transplantation. Treatment consists of a combination of corticosteroids and calcineurin inhibitors. There is no standardized therapy for cases in which this treatment fails. Recent experimental studies and clinical trials in humans have yielded promising results for imatinib, an inhibitor of tyrosine kinase enzymes involved in the pathogenesis of fibrosis. This article reviews pathophysiologic aspects of scleroderma in the context of GVHD and systemic sclerosis, the experimental bases for the use of tyrosine kinase inhibitors in these diseases, and the first clinical results.
authors.affiliation: Unidad de Trasplante Hematopoyético, Servicio de Hematologia, Instituto de Hematología y Oncología, Hospital Clinic, Universidad de Barcelona, Barcelona, España.
authors.forename: C
authors.initials: C
authors.lastname: Martínez
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D001549:Benzamides; D065095:Calcineurin Inhibitors; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology* / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D001549:Benzamides; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases